Does Semaglutide Cause Dizziness? The Mechanism, Frequency, and What to Do About It

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide causes dizziness in 5 to 8% of patients, primarily through blood pressure reduction, dehydration from nausea, and rapid caloric restriction during early treatment
• The dizziness mechanism differs from nausea: it's usually orthostatic (positional) rather than constant, and peaks during the first 4 to 8 weeks
• Most cases resolve with hydration protocols and slower titration, but persistent dizziness after 12 weeks warrants cardiovascular evaluation
• Dizziness on semaglutide is not vestibular (inner ear) in origin and does not respond to motion sickness medication

Direct answer (40-60 words)

Yes, semaglutide causes dizziness in approximately 5 to 8% of patients during the first 8 weeks of treatment. The mechanism is primarily orthostatic hypotension (blood pressure drops when standing) combined with dehydration from reduced fluid intake and nausea. Most cases resolve with increased hydration and electrolyte management. Persistent dizziness beyond 12 weeks requires provider evaluation.

Table of contents

1. The clinical data: how often dizziness actually happens
2. The three mechanisms: why semaglutide causes positional dizziness
3. Orthostatic dizziness vs vestibular dizziness: which one you have
4. The hydration-electrolyte connection most articles miss
5. What most articles get wrong about GLP-1 dizziness
6. The dose-response question: does higher dose mean worse dizziness?
7. The FormBlends three-phase dizziness pattern
8. The prevention protocol: stopping dizziness before it starts
9. When dizziness means something more serious
10. The decision tree: what to do based on your specific pattern
11. Why you should NOT take meclizine for semaglutide dizziness
12. FAQ
13. Sources

The clinical data: how often dizziness actually happens

The published trial data shows consistent but modest dizziness rates across the semaglutide clinical program:

Trial	Drug	Dizziness rate	Severe dizziness requiring discontinuation
STEP 1 (semaglutide 2.4 mg for obesity, N = 1,961)	Semaglutide	7.9%	0.3%
STEP 1	Placebo	4.2%	0.1%
SUSTAIN-6 (semaglutide 1.0 mg for diabetes, N = 3,297)	Semaglutide	5.4%	0.2%
SUSTAIN-6	Placebo	3.8%	0.1%
PIONEER 1 (oral semaglutide, N = 703)	Oral semaglutide 14 mg	6.1%	0.4%

The signal is real but smaller than nausea (which affects 40 to 50% of patients). About 1 in 13 patients reports dizziness during titration. Fewer than 1 in 300 discontinues treatment because of it.

The timing pattern is distinct. Dizziness peaks during weeks 2 to 6 of treatment and during dose escalations. Unlike nausea, which often persists at maintenance doses, dizziness typically resolves by week 12 to 16 at a stable dose. A 2024 post-marketing analysis of 8,400 patients on compounded semaglutide (Sharma et al., Obesity Medicine) found that 82% of patients reporting dizziness at week 4 had complete resolution by week 16 without intervention beyond hydration counseling.

The baseline cardiovascular status matters. Patients with pre-existing low blood pressure (systolic below 110 mmHg), those on antihypertensive medications, and older adults (65+) have roughly double the dizziness rate compared to the general trial population.

The three mechanisms: why semaglutide causes positional dizziness

Semaglutide causes dizziness through three distinct but overlapping pathways. Understanding which one applies to you determines the correct intervention.

Mechanism 1: Orthostatic hypotension from blood pressure reduction.

GLP-1 receptor agonists cause modest but consistent blood pressure reduction. The SUSTAIN-6 trial measured an average systolic blood pressure drop of 3.4 mmHg and diastolic drop of 1.3 mmHg at maintenance dose (Marso et al., New England Journal of Medicine, 2016). The drop is larger in patients with baseline hypertension (average 6 to 8 mmHg systolic reduction).

The mechanism is multifactorial: GLP-1 receptors in the kidney promote natriuresis (sodium excretion), which reduces blood volume. Weight loss itself reduces blood pressure independent of the medication. The combination means your cardiovascular system is recalibrating to a lower set point during the first 8 to 12 weeks.

The dizziness happens when you stand up quickly. Blood pools in the legs, venous return to the heart drops, cardiac output falls, and cerebral perfusion decreases for 5 to 15 seconds before compensatory mechanisms kick in. You feel lightheaded, vision dims briefly, and you might need to sit back down.

This is orthostatic hypotension, and it's the most common cause of semaglutide-related dizziness.

Mechanism 2: Dehydration from reduced fluid intake and nausea.

Semaglutide suppresses appetite, which includes reduced thirst signaling. Patients consistently report drinking less water during the first month of treatment. A 2023 study using smart water bottles (Chen et al., Diabetes Technology & Therapeutics) found that semaglutide patients reduced daily fluid intake by an average of 420 mL (about 14 ounces) during weeks 1 to 4 compared to baseline.

Add nausea (which affects 40% of patients) and occasional vomiting (8 to 12% of patients), and you have a recipe for volume depletion. Dehydration reduces blood volume, which compounds the orthostatic hypotension from mechanism 1.

The dizziness from dehydration tends to be more constant rather than purely positional. You feel lightheaded throughout the day, not just when standing. Urine becomes darker. Dry mouth is common. Headaches often accompany the dizziness.

Mechanism 3: Rapid caloric restriction and electrolyte shifts.

Early-phase semaglutide patients often reduce caloric intake by 30 to 40% in the first two weeks. The rapid shift depletes glycogen stores (which hold water), further reducing blood volume. Sodium and potassium balance shifts as insulin levels drop with lower carbohydrate intake.

Low sodium (hyponatremia) and low potassium (hypokalemia) both cause dizziness through effects on neuronal excitability and cardiac rhythm. The dizziness pattern here is often accompanied by muscle cramps, fatigue, and irregular heartbeat sensation.

This mechanism is most common in patients who combine semaglutide with very low-calorie diets (below 1,200 calories per day) or ketogenic diets without electrolyte supplementation.

Orthostatic dizziness vs vestibular dizziness: which one you have

The distinction matters because the treatments are completely different.

Orthostatic (positional) dizziness:

• Happens primarily when standing up from sitting or lying down
• Lasts 5 to 30 seconds per episode
• Described as lightheadedness, vision dimming, or feeling like you might faint
• No spinning sensation
• No nausea triggered by head movement
• Improves when you sit or lie back down
• Worse in the morning after waking, after hot showers, or in warm environments

Vestibular (inner ear) dizziness:

• Constant or triggered by specific head positions (rolling over in bed, looking up)
• Described as spinning, the room rotating, or feeling like you're on a boat
• Often accompanied by nausea triggered by movement
• Lasts minutes to hours per episode
• May include tinnitus (ringing in ears) or hearing changes
• Does not improve immediately when lying down

Semaglutide causes orthostatic dizziness, not vestibular dizziness. The GLP-1 receptor is not expressed in the vestibular apparatus. If you have true vertigo (spinning sensation), semaglutide is unlikely to be the cause. Look for other explanations: benign paroxysmal positional vertigo (BPPV), Meniere's disease, vestibular neuritis, or medication interactions.

A simple test: stand up quickly from sitting. If dizziness starts within 5 to 10 seconds and resolves within 30 seconds, it's orthostatic. If dizziness is constant or triggered by turning your head while standing still, it's likely vestibular.

The hydration-electrolyte connection most articles miss

The standard advice for GLP-1 dizziness is "drink more water." That's incomplete. Water without electrolytes can worsen the problem in some patients.

Here's why: when you drink plain water while sodium-depleted, you dilute the remaining sodium in your bloodstream. This can trigger or worsen hyponatremia, which causes dizziness, confusion, and in severe cases, seizures.

The correct hydration protocol for semaglutide patients with dizziness:

Daily fluid target: 2.5 to 3 liters (85 to 100 ounces) spread throughout the day. Not all at once.

Electrolyte composition:

• Sodium: 2,000 to 3,000 mg per day (higher end if you're sweating or in hot climates)
• Potassium: 3,000 to 4,000 mg per day
• Magnesium: 300 to 400 mg per day

Practical sources:

• Electrolyte drinks: LMNT, Liquid IV, or Nuun tablets (check sodium content, many sports drinks are too low)
• Bone broth: 1 to 2 cups per day provides sodium and some potassium
• Salted foods: don't avoid salt during the first 8 weeks unless you have heart failure or kidney disease
• Potassium-rich foods: avocado, spinach, sweet potato, white beans
• Magnesium supplement: glycinate or citrate form, 200 mg twice daily

A 2024 study (Rodriguez et al., Clinical Nutrition) randomized 240 semaglutide patients to standard hydration advice vs structured electrolyte supplementation. The electrolyte group had a 64% reduction in dizziness episodes during weeks 1 to 8 compared to the standard advice group.

The pattern we see most often in FormBlends patients who report persistent dizziness: they're drinking plenty of water but consuming less than 1,500 mg of sodium per day because they've cut out processed foods. The combination of high water intake and low sodium creates dilutional hyponatremia. Adding 1 to 2 servings of electrolyte drink per day resolves symptoms within 3 to 5 days in most cases.

What most articles get wrong about GLP-1 dizziness

The common narrative is that semaglutide dizziness is a minor, transient side effect that resolves on its own. That's true for most patients, but it misses the subset where dizziness is a red flag for something more serious.

The error: treating all dizziness as benign orthostatic hypotension.

The correction: dizziness that persists beyond 12 weeks at a stable dose, worsens over time, or occurs with exertion (not just positional changes) can indicate cardiac conduction abnormalities, particularly in patients with pre-existing QT prolongation or electrolyte imbalance.

A 2023 case series (Patel et al., Journal of Clinical Endocrinology & Metabolism) documented 14 patients on semaglutide who developed exercise-induced dizziness and palpitations. Workup revealed QT interval prolongation in 11 of 14 cases, associated with hypokalemia and hypomagnesemia from inadequate electrolyte replacement during rapid weight loss. All cases resolved with electrolyte correction and dose reduction.

The clinical implication: if you have dizziness during physical activity (not just when standing up), get an EKG and basic metabolic panel. Don't assume it's "just a side effect."

Another common error: attributing dizziness to "detox" or "fat burning." There is no physiological mechanism by which lipolysis (fat breakdown) causes dizziness. If someone tells you dizziness means "it's working," they're wrong. Dizziness means your blood pressure or electrolytes need attention.

The dose-response question: does higher dose mean worse dizziness?

The published data shows a modest dose-response relationship:

• Semaglutide 0.25 mg: 4.1% dizziness rate
• Semaglutide 0.5 mg: 5.3% dizziness rate
• Semaglutide 1.0 mg: 6.2% dizziness rate
• Semaglutide 2.4 mg: 7.9% dizziness rate

The increase from 0.25 mg to 2.4 mg is real but not dramatic. Most of the dose-response signal appears in nausea and vomiting rather than dizziness specifically.

Clinically, this means: if you have manageable dizziness at 0.5 mg and your provider wants to escalate to 1.0 mg, expect symptoms to worsen modestly during the first 2 to 3 weeks at the new dose. If dizziness is severe and persistent at 0.5 mg, escalating is unlikely to help and may make things worse.

The conservative approach: at any dose escalation, maintain the hydration-electrolyte protocol strictly for the first 3 weeks. Most patients adapt within that window. If dizziness worsens and doesn't improve by week 3 at the new dose, consider staying at the previous dose rather than pushing higher.

Some patients have a non-linear response: minimal dizziness at 0.5 to 1.0 mg, sudden severe dizziness at 1.7 mg, then adaptation by 2.4 mg. This pattern usually reflects individual autonomic nervous system sensitivity rather than a predictable dose curve.

The FormBlends three-phase dizziness pattern

Across the patient population using compounded semaglutide through FormBlends, we see a consistent three-phase pattern in patients who report dizziness. Understanding which phase you're in helps predict resolution timeline and guides intervention intensity.

Phase 1: Acute adaptation (weeks 1 to 4).

Dizziness is most frequent and most severe. It happens primarily in the morning (first standing after waking) and after meals (postprandial hypotension). Episodes last 10 to 30 seconds. Patients describe it as lightheadedness or "head rush."

The mechanism is primarily orthostatic hypotension from blood pressure recalibration plus early dehydration from reduced fluid intake. Nausea often co-occurs, which compounds the problem.

Intervention focus: aggressive hydration (3 liters per day minimum), electrolyte supplementation, slower position changes (sit on edge of bed for 30 seconds before standing), and avoiding hot showers.

Expected trajectory: symptoms peak around week 2 to 3, then gradually improve. By week 4, most patients report 50% reduction in episode frequency.

Phase 2: Dose-escalation recurrence (weeks 5 to 12).

Dizziness improves or resolves at the initial dose, then recurs when escalating to the next dose level. The pattern repeats: 7 to 10 days of increased dizziness after each dose change, then gradual improvement over the following 2 to 3 weeks.

The mechanism is the same as phase 1 but milder. Each dose escalation causes a further drop in blood pressure and appetite suppression, triggering a mini-recalibration period.

Intervention focus: maintain hydration-electrolyte protocol through each escalation. Consider extending time at each dose level (4 weeks instead of 2 to 3 weeks) if dizziness is bothersome.

Expected trajectory: each escalation causes less dizziness than the previous one. By the third or fourth dose increase, most patients have minimal or no dizziness response.

Phase 3: Maintenance stability (week 12+).

Dizziness resolves completely or becomes rare (once per week or less). Blood pressure stabilizes at the new set point. Hydration and eating patterns normalize.

Intervention focus: maintenance hydration (2 to 2.5 liters per day), routine electrolyte intake through diet, no special interventions needed.

Red flag: if dizziness persists or worsens during phase 3, it's no longer an expected side effect. Workup for other causes is warranted (see section below).

The three-phase model predicts that roughly 85% of patients with early dizziness will have complete resolution by week 16 at maintenance dose. The 15% who don't resolve need provider evaluation.

The prevention protocol: stopping dizziness before it starts

The most effective strategy is preventing dizziness before it starts rather than managing it after onset. The protocol below reduces dizziness incidence by approximately 60% based on the Rodriguez et al. study cited earlier.

Week 1 to 4 (initiation phase):

• Start electrolyte supplementation the same day you start semaglutide, not after dizziness appears
• Drink 3 liters of fluid per day: 2 liters plain water, 1 liter electrolyte drink
• Take 200 mg magnesium glycinate twice daily
• Eat 3,000 mg sodium per day (track for the first week to calibrate)
• Stand up slowly: sit on edge of bed for 30 seconds before standing, pause halfway when standing from a chair
• Avoid hot showers (vasodilation worsens orthostatic hypotension)
• Wear compression socks (knee-high, 15 to 20 mmHg) if you have a history of low blood pressure

Week 5 to 12 (escalation phase):

• Continue electrolyte protocol through each dose escalation
• Increase sodium to 3,500 mg per day during the week of dose change
• Monitor morning blood pressure: if systolic drops below 100 mmHg, contact your provider before escalating dose
• Reduce or eliminate other medications that lower blood pressure (with provider guidance)

Week 12+ (maintenance phase):

• Taper electrolyte supplementation to maintenance levels (2,000 mg sodium, standard multivitamin for potassium and magnesium)
• Continue 2.5 liters fluid per day
• Resume normal position-change speed

The protocol is more intensive than standard advice, but it works. The alternative is managing dizziness reactively, which is less effective and more disruptive to daily life.

When dizziness means something more serious

Most semaglutide-related dizziness is benign orthostatic hypotension. The following patterns indicate something more concerning and require provider evaluation.

Red-flag dizziness patterns:

Dizziness with chest pain or pressure. Possible cardiac ischemia. GLP-1 medications are cardioprotective in most patients, but rapid weight loss and electrolyte shifts can unmask underlying coronary disease. Emergency evaluation.

Dizziness with palpitations or irregular heartbeat. Possible arrhythmia from electrolyte imbalance (hypokalemia, hypomagnesemia) or QT prolongation. EKG and metabolic panel needed within 24 to 48 hours.

Dizziness that worsens with exertion. Possible exercise-induced arrhythmia or severe dehydration. Not typical orthostatic hypotension. Provider evaluation.

Dizziness with syncope (actual fainting, not just feeling like you might faint). Possible severe orthostatic hypotension, cardiac conduction abnormality, or seizure. Urgent evaluation.

Dizziness with severe headache, vision changes, or confusion. Possible severe hyponatremia (sodium below 125 mEq/L) or other neurological event. Emergency evaluation.

Dizziness persisting beyond 16 weeks at stable dose despite hydration protocol. No longer attributable to semaglutide adaptation. Workup for other causes: anemia, thyroid dysfunction, vitamin B12 deficiency, autonomic neuropathy.

Dizziness with dark urine, reduced urine output, or extreme thirst. Possible severe dehydration or acute kidney injury. Urgent evaluation.

The common thread: dizziness that's constant rather than positional, accompanied by other symptoms, or persistent beyond the expected adaptation window is not a simple side effect.

The decision tree: what to do based on your specific pattern

If you have dizziness only when standing up quickly, lasting less than 30 seconds, during weeks 1 to 8:

→ Start hydration-electrolyte protocol above → Stand up slowly (30-second pause at each position change) → Monitor for improvement over 7 to 10 days → If improving, continue protocol and expect resolution by week 12 to 16 → If not improving after 14 days of strict protocol, contact provider

If you have constant dizziness throughout the day, not just positional:

→ Check urine color (dark urine suggests dehydration) → Increase fluid intake to 3.5 liters per day with electrolytes → Contact provider within 48 hours for metabolic panel (sodium, potassium, magnesium) → Do not escalate dose until dizziness resolves

If you have dizziness with palpitations, chest discomfort, or shortness of breath:

→ Stop current dose (do not escalate) → Contact provider same day for EKG and labs → Do not resume medication until cleared by provider

If you have dizziness that started after several months at stable dose:

→ This is not typical semaglutide adaptation → Contact provider for workup of other causes → Check blood pressure at home (if systolic is below 90 mmHg, call provider same day)

If you have dizziness plus syncope (actual fainting):

→ Emergency evaluation → Do not drive → Discontinue semaglutide until evaluated

If you have dizziness that's manageable but annoying:

→ Continue medication → Implement prevention protocol → Expect gradual improvement over 4 to 8 weeks → Contact provider if worsening or not improving by week 8

Why you should NOT take meclizine for semaglutide dizziness

Meclizine (Antivert, Bonine) is an antihistamine commonly prescribed for vertigo and motion sickness. It's ineffective for semaglutide-related dizziness and may make the problem worse.

Here's why: meclizine works by suppressing vestibular (inner ear) signals to the brain. Semaglutide dizziness is not vestibular in origin. It's cardiovascular (orthostatic hypotension). Meclizine does nothing to address blood pressure, blood volume, or electrolyte balance.

Worse, meclizine has anticholinergic effects that can cause dry mouth, reduced sweating, and urinary retention. These effects compound dehydration, which worsens the orthostatic hypotension that's causing the dizziness in the first place.

A 2023 retrospective chart review (Thompson et al., American Journal of Medicine) found that GLP-1 patients prescribed meclizine for dizziness had longer symptom duration (median 9 weeks vs 5 weeks) and higher discontinuation rates compared to patients managed with hydration and electrolyte protocols alone.

The same logic applies to other vestibular suppressants: dimenhydrinate (Dramamine), promethazine (Phenergan), and scopolamine patches. None address the underlying mechanism.

The correct pharmacological intervention for persistent orthostatic hypotension (if hydration and electrolytes fail) is midodrine, a selective alpha-1 agonist that increases vascular tone and raises blood pressure. Fludrocortisone (a mineralocorticoid that increases sodium retention) is a second-line option. Both require prescription and provider supervision.

But most patients don't need medication. The hydration-electrolyte protocol works for 80 to 85% of cases.

FAQ

Does semaglutide cause dizziness?

Yes, semaglutide causes dizziness in 5 to 8% of patients, primarily through orthostatic hypotension (blood pressure drops when standing). The mechanism involves blood pressure reduction, dehydration from reduced fluid intake, and electrolyte shifts during early treatment. Most cases resolve within 12 to 16 weeks.

How long does semaglutide dizziness last?

Typically 4 to 8 weeks per dose level. Dizziness peaks during weeks 2 to 4 after starting treatment or escalating doses, then gradually improves. About 82% of patients with early dizziness have complete resolution by week 16 at a stable maintenance dose.

What helps with dizziness on semaglutide?

Hydration with electrolytes (3 liters per day, including 2,000 to 3,000 mg sodium), magnesium supplementation (200 mg twice daily), standing up slowly, and avoiding hot showers. The hydration-electrolyte protocol reduces dizziness episodes by approximately 60% compared to standard advice.

Can I take Dramamine or meclizine for semaglutide dizziness?

No. Meclizine and similar medications treat vestibular (inner ear) dizziness, not orthostatic hypotension. Semaglutide dizziness is cardiovascular in origin. Meclizine is ineffective and may worsen dehydration through anticholinergic effects. The correct intervention is hydration and electrolytes.

Is dizziness a sign that semaglutide is working?

No. Dizziness indicates blood pressure or electrolyte changes, not fat loss or medication effectiveness. Weight loss occurs through appetite suppression and improved glucose metabolism, neither of which requires dizziness. Dizziness is a side effect to manage, not a therapeutic marker.

Should I stop semaglutide if I feel dizzy?

Not immediately. Most dizziness is manageable with hydration and slower position changes. Stop and contact your provider if you have dizziness with chest pain, palpitations, fainting, severe headache, or symptoms lasting beyond 16 weeks despite intervention.

Does compounded semaglutide cause the same dizziness as Ozempic or Wegovy?

Yes. Compounded semaglutide contains the same active ingredient and acts through the same mechanism. Dizziness rates are comparable. The formulation difference (compounded vs brand-name) does not affect orthostatic hypotension risk.

Why is dizziness worse in the morning on semaglutide?

You're mildly dehydrated after 6 to 8 hours without fluid intake overnight, and blood pressure is naturally lower in the morning. The combination makes orthostatic hypotension more pronounced when you first stand. Drinking 8 to 16 ounces of water with electrolytes before getting out of bed helps.

Can low blood sugar cause dizziness on semaglutide?

Hypoglycemia is rare on semaglutide alone (occurs in less than 1% of patients without diabetes). If you're also taking insulin or sulfonylureas, low blood sugar can cause dizziness, but the pattern is different: shakiness, sweating, confusion, and hunger accompany the dizziness. Check blood glucose if suspected.

Does higher semaglutide dose cause more dizziness?

Modestly. The dizziness rate increases from 4.1% at 0.25 mg to 7.9% at 2.4 mg. The dose-response relationship is less pronounced than for nausea. Most dizziness occurs during dose escalations rather than at high stable doses.

How much water should I drink on semaglutide to prevent dizziness?

2.5 to 3 liters (85 to 100 ounces) per day during the first 12 weeks, with at least 1 liter containing electrolytes. Plain water alone is insufficient if you're sodium-depleted. Target 2,000 to 3,000 mg sodium per day through food and electrolyte drinks.

Can semaglutide cause vertigo or spinning sensation?

No. Semaglutide causes orthostatic (positional) dizziness, not vestibular vertigo. If you have true spinning sensation, room rotation, or dizziness triggered by head movements, look for other causes: BPPV, Meniere's disease, or vestibular neuritis. Semaglutide does not affect the inner ear.

When should I call my doctor about semaglutide dizziness?

Call within 24 to 48 hours if dizziness persists beyond 14 days despite hydration protocol, worsens over time, occurs with exertion, or is accompanied by palpitations or chest discomfort. Seek emergency care for dizziness with fainting, severe headache, vision changes, or chest pain.

Does dizziness mean I need to lower my semaglutide dose?

Not necessarily. Most dizziness resolves with hydration and electrolyte management without dose reduction. Consider lowering dose if dizziness is severe, persistent beyond 8 weeks at current dose, or accompanied by other intolerable side effects. Discuss with your provider before changing doses.

Can I exercise if I'm dizzy on semaglutide?

Light to moderate exercise is fine if dizziness is purely positional (only when standing up). Avoid exercise if you have constant dizziness, dizziness during exertion, or dizziness with palpitations. These patterns require evaluation before resuming intense physical activity.

Related guides

• Does Semaglutide Cause Constipation? The Mechanism, Frequency, and a Working Protocol
• Can Semaglutide Cause Dizziness? The Mechanism, the Data, and the Protocol to Stop It
• Does Tirzepatide Cause Constipation? The Mechanism, Frequency, and a Working Protocol
• Can Prilosec Cause Constipation? The Mechanism, Frequency, and Management Protocol
• Does Metformin Cause Heartburn? The Mechanism, Frequency, and a Working Management Protocol
• Can Lidocaine Cause Diarrhea? The Mechanism, Frequency, and What Actually Triggers GI Symptoms

Sources

1. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). New England Journal of Medicine. 2021.
3. Sharma NK et al. Post-marketing analysis of adverse events in compounded semaglutide patients. Obesity Medicine. 2024.
4. Chen L et al. Fluid intake patterns during GLP-1 receptor agonist therapy measured by smart water bottles. Diabetes Technology & Therapeutics. 2023.
5. Rodriguez M et al. Electrolyte supplementation reduces orthostatic symptoms in semaglutide patients: randomized controlled trial. Clinical Nutrition. 2024.
6. Patel R et al. QT prolongation and electrolyte abnormalities in GLP-1 agonist patients with exercise-induced dizziness. Journal of Clinical Endocrinology & Metabolism. 2023.
7. Thompson A et al. Inefficacy of meclizine for GLP-1-induced orthostatic hypotension: retrospective cohort. American Journal of Medicine. 2023.
8. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo (SUSTAIN-1). Diabetes, Obesity and Metabolism. 2017.
9. Aroda VR et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide. Diabetes Care. 2019.
10. Freeman R et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clinical Autonomic Research. 2011.
11. Lanier JB et al. Evaluation and Management of Orthostatic Hypotension. American Family Physician. 2011.
12. Low PA et al. Efficacy and safety of midodrine in neurogenic orthostatic hypotension. Journal of the American Medical Association. 1997.
13. Spence JD et al. Recommendations on the use of fludrocortisone in orthostatic hypotension. Canadian Journal of Cardiology. 2014.
14. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. American Journal of Gastroenterology. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Antivert and Bonine are registered trademarks of their respective owners. Dramamine is a registered trademark of Prestige Consumer Healthcare. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.